Parkinson's disease and free radicals: Mechanism of neurodegeneration and neuroprotection

Annals of the New York Academy of Sciences

Volumn 786, Issue , 1996, Pages 206-216

  Kondo, Tomoyoshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLORGYLINE; DIMETHYL SULFOXIDE; DOPAMINE; FERROUS ION; FREE RADICAL; HYDROGEN PEROXIDE; MITOCHONDRIAL DNA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINE RELEASE; ELECTRON TRANSPORT; LIPID PEROXIDATION; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 0029763377     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb39063.x     Document Type: Article

References (35)

1. KONDO, K., L. T. KURLAND & W. J. SCHULL. 1973. Parkinson's disease, genetic analysis and evidence of a multifactorial etiology. Mayo Clin. Proc. 48: 465-475.
2. COHEN, G. 1984. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5: 77-82.
3. GRAHAM, D. G. 1978. Oxidative pathway for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14: 633-643.
4. MEUNO, Y., S. IKEBE, N. HATORI, T. KONDO, M. TANAKA & T. OZAWA. 1993. Mitochondrial energy crisis in Parkinson's disease. Adv. Neurol. 60: 282-287.
5. NAOI, M., P. DOSTERT, M. YOSHIDA & T. NAGATSU. 1993. N-Methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv. Neurol. 60: 212-217.
6. OHTA, S., M. KOHNO, Y. MARINO, O. TACHIKAWA & M. HIROBE. 1987. Tetrahydroisoquinoline and 1-methyltetrahydro-isoquinoline are present in the human brain: relation to Parkinson's disease. Biomed. Res. 8: 453-456.
7. RIEDERER, P., E. SOFIC, W-D. RAUSCH, B. SCHMINDT, G. P. REYNOLDS, K. JELLINGER & M. B. YOUDIM. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520.
8. SAGGU, H., J. COOKSEY, D. DEXTER, F. R. WELLS, A. LEES, P. JENNER & D. C. MARSDEN. 1989. A selective increase in paniculate superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53: 692-697.
9. DEXTER, D. T., C. J. CARTER, F. R. WELLS, F. JAVOY-AGID, Y. AGIO, A. LEES, P. JENNER & C. D. MARSDEN. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
10. SHIAN, J., D. T. DEXTER, A. J. LEES, S. DANIEL, Y. AGID, F. JAVOY-AGID, P. JENNER & C. D. MARSDEN. 1994. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36: 348-355.
11. DEXTER, D. T., A. E. HOLLEY, W. D. FLITTER, T. F. SLATER, F. R. WELLS & S. E. DANIEL. 1994. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9: 92-97.
12. BEN-SHACHAR, D., P. RIEDERER & M. B. H. YOUDIM. 1991. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57: 1609-1614.
13. +. J. Neural. Transm. Gen. Sect. 89: 139-145.
14. KONDO, T., T. ITO & Y. SUGITA. 1994. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann. N.Y. Acad. Sci. 738: 222-229.
15. SCHMIDT, C. J., K. RITTER, P. K. SONSALLA, G. R. HANSON & J. W. GIBB. 1985. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233: 539-544.
16. CHIUEH, C. C., R-M. WU, K. P. MOHANAKUMAR, L. M. STERNBERGER, G. KRISHNA, T. OBATA & D. L. MURPHY. 1994. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N.Y. Acad. Sci. 738: 25-36.
17. ZHANG, Y., O. MARCILLAT, C. GIULVI, L. ERNSTER & K. J. A. DAVIS. 1990. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J. Biol. Chem. 165: 16330-16336.
18. MECOCCI, P., U. MACGARVEY, A. E. KAUFMAN, D. KOONTZ, J. M. SHOFFNER, D. C. WALLACE & M. F. BEAL. 1993. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34: 609-616.
19. JENNER, P., D. T. DEXTER, J. SHIAN, A. H. V. SCHAPIRA & C. D. MARSDEN. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 35: 38-44.
20. DEXTER, D. T., J. SIAN, S. ROSE, J. G. HINDMARSH, V. M. MANN, J. M. COOPER, F. R. WELLS, S. E. DANIEL, A. J. LEES, A. H. V. SCHAPIRA, P. JENNER & C. D. MARSDEN. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35: 38-44.
21. MOGI, M., M. HARADA, P. RIEDERER, H. NARABAYASHI, K. FUOTA & T. NAGATSU. 1994. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165: 208-210.
22. MOGI, M., M. HARADA, T. KONDO, P. RIEDERER, H. INAGAKI, M. MINAMI & T. NAGATSU. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180: 147-150.
23. BECKMAN, J. S., T. W. BECKMAN, J. CHEN, P. A. MARSHALL & B. A. FREEMAN. 1990. Aparrent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87: 1620-1624.
24. HIRSCH, E. C., J. P. BRANDEL, P. GALLE, F. JAVOY-AGID & Y. AGID. 1991. Iron and aluminum increases in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451.
25. REIF, D. & R. D. SIMMONS. 1990. Nitric oxide mediates iron from ferritin. Arch. Biochem. Biophys. 283: 537-541.
26. 2+-ADP and the relative unimportance of -OH in the mechanism of mitomycin C-induced lipid peroxidation. Biochim. Biophys. Acta 796: 285-293.
27. 2+) complex. Arch. Biochem. Biophys. 283: 334-341.
28. SCHMIDT, C. J., J. K. RITTER, P. K. SONSALLA, G. R. HANSON & J. W. GIBB. 1985. Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233: 539-544.
29. SEIDEN, L. S. & G. VOSMER. 1984. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methamphetamine. Pharmacol. Biochem. Behav. 21: 29-31.
30. GROOTVELD, M. & B. HALLIWELL. 1986. Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Biochem. J. 237: 499-504.
31. KONDO, T., Y. SUGITA, A. KANAZAWA, T. ITO & Y. MEUNO. 1992. Free dopamine and iron contribute to the hydroxyl radical generation in the methamphetamine induced experimental parkinsonism. Mov. Disord. 17(Suppl. 1): 73.
32. KONDO, T., T. ITO, A. KANAZAWA & Y. MIZUNO. 1993. Degeneration of dopaminergic nerve terminals induced by methamphetamine: study of the mechanism. Clin. Neurol. 33: 1473.
33. ABE, K., H. FUJIMURA, Y. NISHIKAWA, S. YORIFUJI, T. MEZAKI, N. HIRONO, N. NISHITANI & M. KAMEYAMA. 1991. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol. Scand. 83: 356-359.
34. HEIKKILA, R., L. MANZINO, F. S. CABBAT & R. C. DUVOISIN. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469.
35. RICAURTE, G. A., J. W. LANGSTON, L. E. DELANNY, I. IRWIN & J. D. BROOKS. 1985. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci. Lett. 59: 259-264.